Who are Amlodipine+standard antihypertensive therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Diltiazem Injectable Product, nicardipine intravenous, Adalat (Nifedipine, BAYA1040), olmesartan medoxomil and a CCB, nifedipine controlled release tablets, Amlodipine + Simvastatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amlodipine-standard-antihypertensive-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Amlodipine+standard antihypertensive therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Amlodipine+standard antihypertensive therapy (Amlodipine+standard antihypertensive therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker (dihydropyridine). Area: Cardiovascular.

marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Amlodipine+standard antihypertensive therapy (Amlodipine+standard antihypertensive therapy) — Beijing Tiantan Hospital. Amlodipine blocks L-type calcium channels in vascular smooth muscle to reduce blood pressure, used here as part of combination antihypertensive therapy.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Amlodipine+standard antihypertensive therapy TARGET	Amlodipine+standard antihypertensive therapy	Beijing Tiantan Hospital	marketed	Calcium channel blocker (dihydropyridine)	L-type voltage-gated calcium channel
Diltiazem Injectable Product	Diltiazem Injectable Product	Virginia Commonwealth University	marketed	Non-dihydropyridine calcium channel blocker	L-type voltage-gated calcium channel
nicardipine intravenous	nicardipine intravenous	Haseki Training and Research Hospital	marketed	Dihydropyridine calcium channel blocker	L-type voltage-gated calcium channel
Adalat (Nifedipine, BAYA1040)	Adalat (Nifedipine, BAYA1040)	Bayer	marketed	Calcium channel blocker (dihydropyridine)	L-type voltage-gated calcium channel
olmesartan medoxomil and a CCB	olmesartan medoxomil and a CCB	Daiichi Sankyo Co., Ltd.	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor; L-type voltage-gated calcium channel
nifedipine controlled release tablets	nifedipine controlled release tablets	Guangzhou First People's Hospital	marketed	Calcium channel blocker (dihydropyridine)	L-type voltage-gated calcium channel
Amlodipine + Simvastatin	Amlodipine + Simvastatin	University of Pavia	marketed	Calcium channel blocker + HMG-CoA reductase inhibitor (statin)	L-type voltage-gated calcium channel; HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker (dihydropyridine) class)

Bayer · 2 drugs in this class
Beijing Tiantan Hospital · 2 drugs in this class
GlaxoSmithKline · 1 drug in this class
Guangzhou First People's Hospital · 1 drug in this class
Organon and Co · 1 drug in this class
Peking University First Hospital · 1 drug in this class
Pfizer Inc. · 1 drug in this class
SK Chemicals Co., Ltd. · 1 drug in this class
Shanghai Jiao Tong University School of Medicine · 1 drug in this class
Shanghai Shyndec Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amlodipine+standard antihypertensive therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipine-standard-antihypertensive-therapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab